Edward Lawrence interviews Wolfgang Wienand, CEO of Lonza Group, a leading pharmaceutical contract developer, about their multi-billion dollar expansion across five U.S. states. The CEO confirms that U.S. administration policies, including potential tariffs on imported medications without domestic manufacturing, played a role in their decision to bring manufacturing back to the U.S.